Jemperli (dostarlimab-gxly) Injection
Drug company: GlaxoSmithKline
844-447-5662
GSK Oncology offers 2 financial assistance programs for patients using Jemperli:
Together with GSK Oncology Commercial Co-pay Program
Patient Assistance Program
Keytruda (pembrolizumab)
Drug company: Merck
855-257-3932
Merck offers 2 financial assistance programs for patients using Keytruda:
Merck Co-pay Assistance Program
Merck Patient Assistance Program
Lenvima (lenvatinib) Capsules
Drug company: Eisai
866-613-4724
Eisai offers 2 financial assistance programs for patients using Lenvima:
Lenvima $0 Co-Pay Program
Lenvima Patient Assistance Program
Table. Drugs Prescribed for Endometrial (Uterine) Cancer
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Jemperli (dostarlimab-gxly) Injection
- GSK Oncology
- Treatment of adults with recurrent or advanced endometrial cancer and dMMR, as determined by an FDA-approved test, that has progressed during or after treatment with a platinum-containing regimen
- Together with GSK Oncology Commercial Co-pay Program
844-447-5662
Jemperli Patient Assistance Program
844-447-5662
Drug name (generic name)
Drug company
Indication
Patient support services
- Keytruda (pembrolizumab)
- Merck
- Treatment, in combination with
Lenvima, of patients with advanced
endometrial carcinoma without
MSI-H abnormality or dMMR, whose
disease progressed after systemic
therapy and who are not candidates
for curative surgery or radiation
As a single agent, for patients with advanced endometrial carcinoma that is MSI-H or dMMR whose disease progressed after systemic therapy and who are not candidates for curative surgery or radiation - Merck Co-pay Assistance Program
855-257-3932
Merck Patient Assistance Program
855-257-3932
Drug name (generic name)
Drug company
Indication
Patient support services
- Lenvima (lenvatinib) Capsules
- Eisai
- Treatment, in combination with Keytruda, of patients with advanced endometrial carcinoma without MSI-H abnormality or dMMR, whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation
- Lenvima $0 Co-Pay Program
866-613-4724
Lenvima Patient Assistance Program
866-613-4724
Drug name (generic name)
Drug company
Indication
Patient support services